ArticleCancer communications (London, England)2021
Impact of diabetes on promoting the growth of breast cancer.
Article in Cancer communications (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- An 8-gene diabetes-related signature predicts survival and immunotherapy response in breast cancer.Clinics (Sao Paulo, Brazil) · 2026Article
- Organic small-molecule NIR-II fluorophores for tumor phototheranostics.Light, science & applications · 2026Review
- The impact of chronic comorbidities on cancer immunoediting: challenges and opportunities for immunotherapies.Frontiers in immunology · 2026Review
- Comparison of nine insulin resistance surrogates for predicting cardiovascular disease: a cohort study.Diabetology & metabolic syndrome · 2025Article
- [Overview of the prevalence and features of oncological diseases in type 2 diabetes and possible immunological mechanisms].Problemy endokrinologii · 2025Review
- Article
- Shared Genomic Features Between Lung Adenocarcinoma and Type 2 Diabetes: A Bioinformatics Study.Biology · 2025Article
- Poorly controlled type II diabetes mellitus significantly enhances postoperative chemoresistance in patients with stage III colon cancer.World journal of gastroenterology · 2025Article
- Multi-omics insights into biomarkers of breast cancer associated diabetes: a computational approach.Frontiers in medicine · 2025Article
- Synergistic Potential of GLP-1 Receptor Agonists and Radiotherapy in Breast Cancer Treatment: A New Therapeutic Avenue (TROD-GROG 006).Current radiopharmaceuticals · 2025Article
- Efficacy and safety of nanoparticle albumin‑bound paclitaxel compared with solvent‑based paclitaxel in adjuvant therapy for breast cancer: A retrospective study.Oncology letters · 2024Article
- Influence of Type 2 Diabetes and Adipose Tissue Dysfunction on Breast Cancer and Potential Benefits from Nutraceuticals Inducible in Microalgae.Nutrients · 2024Review
- Association between triglyceride glucose index and breast cancer in 142,184 Chinese adults: findings from the REACTION study.Frontiers in endocrinology · 2024Article
- The Metabolomic Characteristics and Dysregulation of Fatty Acid Esters of Hydroxy Fatty Acids in Breast Cancer.Metabolites · 2023Article
- Global burden of female breast cancer and its association with socioeconomic development status, 1990-2044.Cancer reports (Hoboken, N.J.) · 2023Article
- Association of high insulin receptor expression with poor prognosis in patients with breast cancer.Gland surgery · 2023Article
- Association between diabetes status and breast cancer in US adults: findings from the US National Health and Nutrition Examination Survey.Frontiers in endocrinology · 2023Article
- Metformin inhibits melanoma cell metastasis by suppressing the miR-5100/SPINK5/STAT3 axis.Cellular & molecular biology letters · 2022Article
- Review
- Harness the functions of gut microbiome in tumorigenesis for cancer treatment.Cancer communications (London, England) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundType II diabetes mellitus (DM2) is a significant risk factor for cancers, including breast cancer. However, a proper diabetic breast cancer mouse model is not well-established for treatment strategy design. Additionally, the precise diabetic signaling pathways that regulate cancer growth remain unresolved. In the present study, we established a suitable mouse model and demonstrated the pathogenic role of diabetes on breast cancer progression.
methodsWe successfully generated a transgenic mouse model of human epidermal growth factor receptor 2 positive (Her2
resultsTreatment with metformin/rosiglitazone in MMTV-ErbB2/Lepr
conclusionsMMTV-ErbB2/Lepr
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.